ARKG vs FBTC
ARK Genomic Revolution ETF vs Fidelity Wise Origin Bitcoin Fund
ARKG$30.38
ARK Genomic Revolution ETF
Companies advancing genomics and molecular biology.
Expense: 0.75%Yield: 0.00%
FBTC$69.80
Fidelity Wise Origin Bitcoin Fund
Spot Bitcoin ETF from Fidelity.
Expense: 0.25%Yield: 0.00%
Quick take
- • FBTC has the lower expense ratio at 0.25% vs 0.75% for ARKG.
Side-by-side metrics
| Metric | ARKG | FBTC |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.25% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.00% |
AUM Assets under management — bigger funds are typically more liquid. | $1.24B | $14.17B |
YTD return | 7.21% | -6.97% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.35 | 0.00 |
P/E ratio | — | — |
Last price | $30.38 | $69.80 |
Inception | — | — |
Issuer | ARK | Fidelity |
ARKG top holdings
Top holdings · ARKG
| TEM | Tempus AI Inc Class A common stock | 9.45% |
| TWST | Twist Bioscience Corp | 9.02% |
| CRSP | CRISPR Therapeutics AG | 8.94% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 5.78% |
| BEAM | Beam Therapeutics Inc | 5.44% |
| ABSI | Absci Corp | 4.79% |
| NTRA | Natera Inc | 4.08% |
| ILMN | Illumina Inc | 4.04% |
| NTLA | Intellia Therapeutics Inc | 3.83% |
| PSNL | Personalis Inc | 3.59% |
Sector breakdown · ARKG
Healthcare100.0%
FBTC top holdings
Holdings data unavailable for FBTC.
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Tempus AI Inc Class A common stock (TEM), which represents 9.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About FBTC
FBTC (Fidelity Wise Origin Bitcoin Fund) is Spot Bitcoin ETF from Fidelity. Managed by Fidelity, the fund carries $14.2B in assets under management, an expense ratio of 0.25%.